Ownership and insider activity for Nuvalent, Inc. (NUVL): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain.
Price
| Price | $123.96 |
| Market Cap | $9.1B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-07-15 | Flynn James E | D-Return | 650,000 | $80.6M |
| 2026-07-15 | Flynn James E | U-Tender | 5,146 | $638K |
| 2026-07-15 | Flynn James E | D-Return | 3,444 | $427K |
| 2026-07-15 | Flynn James E | D-Return | 2,717,627 | |
| 2026-07-15 | Flynn James E | D-Return | 43,000 | $731K |
| 2026-07-15 | Flynn James E | D-Return | 20,000 | $187K |
| 2026-07-15 | Flynn James E | D-Return | 15,000 | $670K |
| 2026-07-15 | Flynn James E | D-Return | 3,789 | $303K |
| 2026-07-15 | Flynn James E | D-Return | 4,147 | $313K |
| 2026-07-15 | Meyers Michael L. | U-Tender | 5,146 | $638K |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.0M | $10.3M | $68.5M | $241.8M | $335.4M | $145.7M | $261.7M |
| Short-term Investments | 0 | 0 | $219.6M | $230.4M | $384.5M | $972.6M | $1.11B |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $3.3M | $10.6M | $290.6M | $478.0M | $726.5M | $1.13B | $1.39B |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $3.3M | $10.6M | $293.8M | $482.5M | $732.4M | $1.14B | $1.41B |
| Accounts Payable | $723000 | $1.3M | $2.9M | $7.2M | $9.3M | $5.2M | $30.2M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $4.4M | $4.4M | $8.8M | $19.5M | $31.8M | $54.0M | $91.2M |
| Long-term Debt | $2.2M | $2.2M | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $20.6M | $42.0M | $8.8M | $19.5M | $31.8M | $72.0M | $164.4M |
| Retained Earnings | -$17.3M | -$31.9M | -$78.2M | -$160.1M | -$286.3M | -$547.1M | -$972.4M |
| Total Equity | -$17.3M | -$31.3M | $285.0M | $463.0M | $700.6M | $1.07B | $1.25B |
| Total Debt | $2.2M | $2.2M | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -$843000 | -$8.1M | -$288.1M | -$472.2M | -$719.9M | -$1.12B | -$1.37B |
| Working Capital | -$1.0M | $6.3M | $281.8M | $458.5M | $694.7M | $1.08B | $1.30B |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 16.14 |
Profitability
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ABVX · ARWR · AXSM · CRSP · CYTK · JAZZ · MRUS
Explore sector: Healthcare · Biotechnology
More sections of NUVL: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks